{
    "ticker": "MNTX",
    "name": "MannKind Corporation",
    "description": "MannKind Corporation is a biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic products for patients with endocrine and metabolic diseases, particularly diabetes. Founded in 1991 and headquartered in Danbury, Connecticut, MannKind is best known for its revolutionary inhaled insulin product, Afrezza, which offers a unique and convenient alternative to traditional insulin therapies. The company focuses on leveraging its proprietary Technosphere\u00ae platform to develop inhalable medications that provide effective treatment options for chronic conditions. MannKind aims to improve the quality of life for patients through easier administration and better glycemic control. With a commitment to advancing diabetes care, the company is also exploring additional applications of its platform technology in other therapeutic areas. MannKind's strategic partnerships and collaborations further enhance its ability to innovate and deliver valuable products to the market. The company is driven by a mission to empower patients and transform diabetes management through cutting-edge science and technology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Danbury, Connecticut, USA",
    "founded": "1991",
    "website": "https://www.mannkindcorp.com",
    "ceo": "Michael Castagna",
    "social_media": {
        "twitter": "https://twitter.com/MannKindCorp",
        "linkedin": "https://www.linkedin.com/company/mannkind-corporation/"
    },
    "investor_relations": "https://investors.mannkindcorp.com",
    "key_executives": [
        {
            "name": "Michael Castagna",
            "position": "CEO"
        },
        {
            "name": "Cheryl McCormick",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Diabetes Care",
            "products": [
                "Afrezza"
            ]
        }
    ],
    "seo": {
        "meta_title": "MannKind Corporation | Innovative Diabetes Care",
        "meta_description": "Learn about MannKind Corporation, a leader in innovative diabetes therapies. Discover their inhaled insulin product Afrezza and commitment to patient care.",
        "keywords": [
            "MannKind",
            "Diabetes",
            "Afrezza",
            "Inhaled Insulin",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does MannKind specialize in?",
            "answer": "MannKind specializes in developing innovative therapies for diabetes management, particularly through its inhaled insulin product Afrezza."
        },
        {
            "question": "Who is the CEO of MannKind?",
            "answer": "Michael Castagna is the CEO of MannKind Corporation."
        },
        {
            "question": "Where is MannKind headquartered?",
            "answer": "MannKind is headquartered in Danbury, Connecticut, USA."
        },
        {
            "question": "What is Afrezza?",
            "answer": "Afrezza is an inhaled insulin product developed by MannKind for the treatment of diabetes."
        },
        {
            "question": "When was MannKind founded?",
            "answer": "MannKind was founded in 1991."
        }
    ],
    "competitors": [
        "PFE",
        "SNY",
        "BAYRY",
        "NOVO"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}